Molecular genotyping of adrenocortical carcinoma: a systematic analysis of published literature 2019-2021.
Journal
Current opinion in oncology
ISSN: 1531-703X
Titre abrégé: Curr Opin Oncol
Pays: United States
ID NLM: 9007265
Informations de publication
Date de publication:
01 01 2022
01 01 2022
Historique:
pubmed:
21
10
2021
medline:
3
5
2022
entrez:
20
10
2021
Statut:
ppublish
Résumé
comprehensive molecular characterization of adrenocortical carcinoma (ACC) through next-generation sequencing and bioinformatics analyses is expanding the number of targets with potential prognostic and therapeutic value. We performed a critical review of recent published literature on genotyping of ACC. 423 studies were published between 2019 and 2021. After manual curation we summarized selected evidence in two thematic areas: germline deoxyribonucleic acid (DNA) variations, genomic alterations and prognosis. the evolving genomic landscape of ACC requires target validation in terms of prognostic and predictive value within scientific consortia. Although the existing multiple driver genes are difficult targets in the perspective of precision oncology, alterations in DNA damage repair genes or in promoter hypermethylation could open new venues for repurposing of existing drugs in ACC.
Identifiants
pubmed: 34669649
doi: 10.1097/CCO.0000000000000799
pii: 00001622-202201000-00004
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
19-28Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Références
Terzolo M, Daffara F, Ardito A, et al. Management of adrenal cancer: a 2013 update. J Endocrinol Investig 2014; 37:207–217.
Fassnacht M, Dekkers OM, Else T, et al. European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol 2018; 179:G1–G46.
Laganà M, Grisanti S, Cosentini D, et al. Efficacy of the EDP-M scheme plus adjunctive surgery in the management of patients with advanced adrenocortical carcinoma: the Brescia experience. Cancers 2020; 12:941.
Grisanti S, Cosentini D, Laganà M, et al. Are we failing in treatment of adrenocortical carcinoma? Lights and shadows of molecular signatures. Curr Opin Endocr Metab Res 2019; 8:80–87.
Assié G, Letouzé E, Fassnacht M, et al. Integrated genomic characterization of adrenocortical carcinoma. Nat Genet 2014; 46:607–612.
Juhlin CC, Goh G, Healy JM, et al. Whole-exome sequencing characterizes the landscape of somatic mutations and copy number alterations in adrenocortical carcinoma. J Clin Endocrinol Metab 2015; 100:E493–502.
Zheng S, Cherniack AD, Dewal N, et al. Comphrehensive Pan-Genomic characterization of adrenocortical carcinoma. Cancer Cell 2016; 29:723–736.
Berger MF, Mardis ER. The emerging clinical relevance of genomics in cancer medicine. Nat Rev Clin Oncol 2018; 15:353–365.
Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. British Med J 2021; 372:n71.
Penny MK, Finco I, Hammer DG. Cell signaling pathways in the adrenal cortex: links to stem/progenitor biology and neoplasia. Mol Cell Endocrinol 2017; 445:42–54.
Pittaway JFH, Guasti L. Pathobiology and genetics of adrenocortical carcinoma. J Molecular Endocrinol 2019; 62:R105.R119.
Ronchi CL. cAMP/protein kinase A signaling pathway and adrenocortical adenomas. Curr Opin Endocr Metab Res 2019; 8:15–21.
Else T. Association of adrenocortical carcinoma with familial cancer susceptibility syndromes. Mol Cell Endocrinol 2012; 351:66–70.
Jouinot A, Bertherat J. Diseases predisposing to adrenocortical malignancy (LI-Fraumeni syndrome, Beckwith-Wiedemann syndrome, and Carney complex). Exp Suppl 2019; 111:149–169.
Gimenez-Roqueplo AP. Adrenal tumors: when to search for a germline abnormality? Curr Opin Oncol 2019; 31:230–235.
Else T, Lerario AM, Everett J, et al. Adrenocortical carcinoma and succinate dehydrogenase gene mutations: an observational case series. Eur J Endocrinol 2017; 177:439–444.
Stratakis CA, Berthon A. Molecular mechanisms of ARMC5 mutations in adrenal pathophysiology. Curr Opin Endocr Metab Res 2019; 8:104–111.
Fassnacht M, Berruti A, Baudin E, et al. Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomized, phase 3 study. Lancet Oncol 2015; 16:426–435.
Knijnenburg TA, Wang L, Zimmermann MT, et al. Genomic and molecular landscape of DNA damage repair deficiency across The Cancer Genome Atlas. Cell Rep 2018; 23:239–254.
Raymond VM, Everett JN, Furtado LV, et al. Adrenocortical carcinoma is a Lynch Syndrome-associated cancer. J Clin Oncol 2013; 31:3012–3018.
Bonneville R, Krook MA, Kautto EA, et al. Landscape of microsatellite instability across 39 cancer types. JCO Precis Oncol 2017; 2017: PO.17.00073.
Yarchoan M, Albacker LA, Hopkins AC, et al. PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers. JCI Insight 2019; 4:e126908.
Rechache NS, Wang Y, Stevenson HS, et al. DNA methylation profiling identifies global methylation differences and markers of adrenocortical tumors. J Clin Endocrinol Metab 2012; 97:E1004–E1013.
Fonseca AL, Kugelberg J, Starker LF, et al. Comprehensive DNA methylation analysis of benign and malignant adrenocortical tumors. Genes Chromosom Cancer 2012; 51:949–960.
Ettaieb M, Kerkhofs T, van Engeland M, et al. Past, present and future of epigenetics in adrenocortical carcinoma. Cancers 2020; 12:1218.
Crona J, Beuschlein F. Adrenocortical carcinoma – towards genomics guided clinical care. Nat Rev Endocrinol 2019; 15:548–560.
Mohan DR, Lerario AM, Hammer GD. Therapeutic targets for adrenocortical carcinoma in the genomics era. J Endocr Soc 2018; 2:1259–1274.
Thavaneswaran S, Rath E, Tucker K, et al. Therapeutic implications of germline genetic findings in cancer. Nat Rev Clin Oncol 2019; 16:386–396.
Brenna CTA, Michaeli O, Wasserman JD, et al. Clinical outcomes of children with adrenocortical carcinoma in the context of germline TP53 status. J Pediatr Hematol Oncol 2021; 43:e635–e641.
Ferreira AM, Brondani VB, Helena VP, et al. Clinical spectrum of Li-Fraumeni syndrome/Li-Fraumeni-like syndrome in Brazilian inviduals with TP53 p.R337H mutation. J Steroid Biochem Mol Biol 2019; 190:250–255.
Wang W, Han R, Ye L, et al. Adrenocortical carcinoma in patients with MEN1: a kindred report and review of literature. Endocr Conn 2019; 8:230–238.
Akhavanfard S, Yehia L, Padmanabhan R, et al. Germline EGFR variants are over-expressed in adolescents and young adults (AYA) with adrenocortical carcinoma. Hum Mol Genet 2021; 29:3679–3690.
Surakhy M, Wallace M, Bond E, et al. A common polymorphism in the retinoic acid pathway modifies adrenocortical carcinoma age-dependent incidence. Br J Cancer 2020; 122:1231–1241.
Pinto EM, Faucz FR, Paza LZ, et al. Germline variants in phosphodiesterase genes and genetic predisposition to pediatric adrenocortical tumors. Cancers 2020; 12:506.
Altieri B, Sbiera S, Herterich S, et al. Effect of germline CYP2W1∗6 and CYP2B6∗6 single nucleotide polymorphisms on mitotane treatment in adrenocortical carcioma: a multicenter ENSAT study. Cancers (Basel) 2020; 12:359.
Xie C, Tanakchi S, Raygada M, et al. Case report of an adrenocortical carcinoma associated with germlne CHEK2 mutation. J Endocr Soc 2018; 3:284–290.
Raygada M, Raffeld M, Bernstein A, et al. Case report of adrenocortical carcinoma associated with double germline mutations in MSH2 and RET. Am J Med Genet A 2021; 185:1282–1287.
Landwehr LS, Schreiner J, Appenzeller S, et al. A novel patient-derived cell line of adrenocortical carcinoma shows a pathogenetic role of germline MUTYH mutation and high tumour mutational burden. Eur J Endocrinol 2021; 184:823–835.
Nicolson NG, Healy JM, Korah R, et al. Whole-exome sequencing of syndromic adrenocortical carcinoma reveals distinct mutational profile from sporadic ACC. J Endocr Soc 2019; 3:1819–1824.
McCabe MJ, Pinese M, Chan CL. Genomic stratification and liquid biopsy in arare adrencortical carcinoma (ACC) case, with dual lung metastases. Cold Spring Harb Mol Case Stud 2019; 5:a003764.
Kaur RJ, Pichurin PN, Hines JM, et al. Adrenal cortical carcinoma associated with Lynch syndrome: a case report and review of literature. J Endocr Soc 2019; 3:784–790.
Tang YJ, Yu TT, Ma J, et al. Composite adrenocortical carcinoma and neuroblastoma in an infant with a TP53 germline mutation: a case report and literature review. J Pediatr Hematol Oncol 2019; 41:399–401.
Gagnon N, Boily P, Alguire C, et al. Small adrenal incidentaloma becoming an aggressive adrenocortical carcinoma in a patient carrying a germline APC variant. Endocrine 2020; 68:203–209.
Bondy S, Tajzler C, Hotte SJ, et al. Genomic and clinical correlates of adrenocortical carcinoma in an adult patient with Li-Fraumeni syndrome: a case report. Curr Oncol 2020; 28:226–232.
Suda K, Fukuoka H, Yamazaki Y, et al. Cardiac myxoma caused by fumarate-hydratase gene deletion in patients with cortisol-secreting adrenocortical adenoma. J Clin Endocrinol Metab 2020; 105:dgaa163.
Feitosa JADS, das Chagas PF, de Sousa GR, et al. Frequency of the TP53 p.R337H mutation in a Brazilian cohort of pediatric patients with solid tumors. Mol Biol Rep 2020; 47:6439–6443.
Takeoka M, Toyoda H, Hirayama J, et al. Report of 2 pediatric cases with Li-Fraumeni syndrome related malignancy in a family. J Pediatr Hematol Oncol 2021; 43:e567–e570.
Domenech M, Grau E, Solanes A, et al. Characteristics of adrenocortical carcinoma associated with Lynch Syndrome. J Clin Endocrinol Metab 2021; 106:318–325.
Torres MB, Diggs LP, Wei JS, et al. Ataxia teleangectasia mutated germline pathogenetic variant in adrenocortical carcinoma. Cancer Genet 2021; 256-257:21–25.
Lippert J, Appenzeller S, Liang R, et al. Targeted molecular analysis in adrenocortical carcinomas: a strategy toward improved personalized prognostication. J Clin Endocrinol Metab 2018; 103:4511–4523.
Assie G, Jouinot A, Fassnacht M, et al. Value of molecular classification for prognostic assessment of adrenocortical carcinoma. JAMA Oncol 2019; 5:1440–1447.
Mohan DR, Lerario AM, Else T, et al. Targeted assessment of G0S2 methylation identifies a rapidly recurrent, routinely fatal molecular subtype of adrenocortical carcinoma. Clin Cancer Res 2019; 25:3276–3288.
Xia WX, Yu Q, Li GH, et al. Identification of four hub genes associated with adrenocortical crcinoma progression by WGCNA. PeerJ 2019; 7:e6555.
Liang J, Liu Z, Wei X, et al. Expression of FSCN1 and FOXM1 are associated with poor prognosis of adrenocortical carcinoma patients. BMC Cancer 2019; 19:1165.
Xiao H, He W, Chen P, et al. Identification of seven aberrantly methylated and expressed genes in adrenocortical carcinoma. Front Endocrinol 2019; 10:472.
Subramanian C, Cohen MS. Over expression of DNA damage and cell cycle dependent proteins are associated with poor survival in patients with adrenocortical carcinoma. Surgery 2019; 165:202–210.
Gao Z, Man X, Li Z, et al. Expression profiles analysis identifies the values of carcinogenesis and the prognostic prediction of three genes in adrenocortical carcinoma. Oncol Rep 2019; 41:2440–2452.
Bulzico D, Pires BRB, De Faria PAS, et al. Twist1 correlates with epithelial-mesenchymal transition markers fibronectin and vimentin in adrenocortical tumors. Anticancer Res 2019; 39:173–175.
Zhu B, Zhi Q, Xie Q, et al. Reduced expression of ferroportin1 and ceruloplasmin predicts poor prognosis in adrenocortical carcinoma. J Trace Elem Med Biol 2019; 56:52–59.
Li H, Liu J, Shen S, et al. Pan-cancer analysis of alternative splicing regulator heterogeneous nuclear ribonucleoproteins (hnRNPs) family and their prognostic potential. J Cell Mol Med 2020; 24:11111–11119.
Creemers SG, Feelders RA, Valdes N, et al. The IGF2 methylation score for adrenocortical cancer: an ENSAT validation study. Endocr Relat Cancer 2020; 27:541–550.
Jouinot A, Lippert J, Fassnacht M, et al. Intratumor heterogeneity of prognostic DNA-based molecular markers in adrenocortical carcinoma. Endocr Connect 2020; 9:705–714.
Knott EL, Leidenheimer NJ. A targeted bioinformatics assessment of adrenocortical carcinoma reveals prognostic implications of GABA system gene expression. Int J Mol Sci 2020; 21:8485.
Xu N, Ke ZB, Lin XD, et al. Identification of survival-associated alternative splicing events and signatures in adrenocortical carcinoma based on TCGA SpliceSeq data. Aging 2020; 12:4996–5009.
Dos Santos Passaia B, Lima K, Kremer JL, et al. Stathmin 1 is highly expressed and associated with survival outcome in malignant adrenocortical tumours. Invest New Drugs 2020; 38:899–908.
Pennanen M, Tynninen O, Kytölä S, et al. IDH1 Expression via the R132H mutation-specific antibody in adrenocortical neoplasias-prognostic impact in carcinomas. J Endocr Soc 2020; 4:bvaa018.
B Li X, Gao Y, Zu Z, et al. Identification of prognostic genes in adrenocortical carcinoma microenvironment based on bioinformatic methods. Cancer Med 2020; 9:1161–1172.
Fojo T, Huff L, Litman T, et al. Metastatic and recurrent adrenocortical cancer is not defined by its genomic landscape. BMC Med Genomics 2020; 13:165.
Yan X, Guo ZX, Yu DH, et al. Identification and validation of a novel prognosis prediction model in adrenocortical carcinoma by integrative bioinformatics analysis, statistics, and machine learning. Front Cell Dev Biol 2021; 9:671359.
Gara SK, Lack J, Zhang L, et al. Metastatic adrenocortical carcinoma displays higher mutation and tumor heterogeneity than primary tumors. Nat Commun 2018; 9:4172.
Yang Z, Cheng H, Zhang Y, et al. Identification of NDRG family member 4 (NDRG4) and CDC28 protein kinase regulatory subunit 2 (CKS2) as key prognostic genes in adrenocortical carcinoma by transcriptomic analysis. Med Sci Monit 2021; 27:e928523.
Deng C, Guo H, Yan D, et al. Pancancer analysis of neurovascular-related NRP family genes as potential prognostic biomarkers of bladder Urothelial Carcinoma. Biomed Res Int 2021; 2021:5546612.
Shen C, Liu J, Yang X, et al. Development and validation of an m6A RNA methylation regulators-based signature for predicting the prognosis of adrenocortical carcinoma. Front Endocrinol 2021; 12:568397.
Fu Y, Sun S, Bi J, et al. Expression patterns and prognostic value of m6A RNA methylation regulators in adrenocortical carcinoma. Medicine 2021; 100:e25031.
Xu F, Guan Y, Ma Y, et al. Bioinformatic analyses and experimental validation of the role of m6A RNA methylation regulators in progression and prognosis of adrenocortical carcinoma. Aging 2021; 13:11919–11941.
Pozdeyev N, Fishbein L, Gay LM, et al. Targeted genomic analysis of 364 adrenocortical carcinomas. Endocr Relat Cancer 2021; 28:671–681.
Thorsson V, Gibbs DL, Brown SD, et al. The immune landscape of cancer. Immunity 2018; 48:812–830.
Sayaman RS, Saad M, Thorsson V, et al. Germline genetic contribution to the immune landscape of cancer. Immunity 2021; 54:367–386.
Boran ADW, Iyengar R. Systems approaches to polypharmacology and drug discovery. Curr Opin Drug Discov Dev 2010; 13:297–309.
Peng X, Chen Z, Farshidfar F, et al. Molecular characterization and clinical relevance of metabolic expression subtypes in human cancers. Cell Rep 2018; 23:255–269.
Mohan DR, Lerario AM, Finco I, et al. New strategies for applying targeted therapies to adrenocortical carcinoma. Curr Opin Endocr Metab Res 2019; 8:72–79.
Alyateem G, Nilubol N. Current status and future target therapy in adrenocortical cancer. Front Endocrinol 2021; 12:613248.